JP2002104962A5 - - Google Patents

Download PDF

Info

Publication number
JP2002104962A5
JP2002104962A5 JP2000341840A JP2000341840A JP2002104962A5 JP 2002104962 A5 JP2002104962 A5 JP 2002104962A5 JP 2000341840 A JP2000341840 A JP 2000341840A JP 2000341840 A JP2000341840 A JP 2000341840A JP 2002104962 A5 JP2002104962 A5 JP 2002104962A5
Authority
JP
Japan
Prior art keywords
disease
therapeutic agent
agent according
prophylactic
inflammatory bowel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000341840A
Other languages
Japanese (ja)
Other versions
JP2002104962A (en
JP3587247B2 (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2000341840A priority Critical patent/JP3587247B2/en
Priority claimed from JP2000341840A external-priority patent/JP3587247B2/en
Publication of JP2002104962A publication Critical patent/JP2002104962A/en
Application granted granted Critical
Publication of JP3587247B2 publication Critical patent/JP3587247B2/en
Publication of JP2002104962A5 publication Critical patent/JP2002104962A5/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Claims (14)

式（Ｉ）：
Figure 2002104962
で示される化合物またはその薬理学的に許容しうる塩を有効成分としてなることを特徴とする炎症性腸疾患の予防・治療剤。Formula (I):
Figure 2002104962
 A prophylactic / therapeutic agent for inflammatory bowel disease comprising a compound represented by the above or a pharmacologically acceptable salt thereof as an active ingredient. 式（Ｉ）で示される化合物の薬理学的に許容しうる塩がスルホデヒドロアビエチン酸・モノナトリウム塩である請求項１記載の予防・治療剤。  The prophylactic / therapeutic agent according to claim 1, wherein the pharmacologically acceptable salt of the compound represented by formula (I) is sulfodehydroabietic acid monosodium salt. 剤形が経口投与用製剤または腸内注入用製剤である請求項１または２記載の予防・治療剤。  The prophylactic / therapeutic agent according to claim 1 or 2, wherein the dosage form is a preparation for oral administration or a preparation for intestinal injection. 炎症性腸疾患が、クローン病もしくはベーチェット病における腸管の病変、潰瘍性大腸炎、出血性直腸潰瘍または回腸嚢炎から選ばれる疾患である請求項１記載の予防・治療剤。  The prophylactic / therapeutic agent according to claim 1, wherein the inflammatory bowel disease is a disease selected from lesions of the intestinal tract in Crohn's disease or Behcet's disease, ulcerative colitis, hemorrhagic rectal ulcer, or ileal cystitis. 炎症性腸疾患が、クローン病もしくはベーチェット病における腸管の病変、または潰瘍性大腸炎から選ばれる疾患である請求項１記載の予防・治療剤。  The prophylactic / therapeutic agent according to claim 1, wherein the inflammatory bowel disease is a disease selected from lesions of the intestinal tract in Crohn's disease or Behcet's disease, or ulcerative colitis. 炎症性腸疾患が、クローン病における腸管の病変である請求項１記載の予防・治療剤。  The preventive / therapeutic agent according to claim 1, wherein the inflammatory bowel disease is a lesion of the intestinal tract in Crohn's disease. クローン病における腸管の病変が、瘻孔である請求項６記載の予防・治療剤。  The preventive / therapeutic agent according to claim 6, wherein the lesion of the intestinal tract in Crohn's disease is a fistula. 炎症性腸疾患が、ベーチェット病における腸管の病変である請求項１記載の予防・治療剤。  The prophylactic / therapeutic agent according to claim 1, wherein the inflammatory bowel disease is an intestinal lesion in Behcet's disease. 炎症性腸疾患が、潰瘍性大腸炎である請求項１記載の予防・治療剤。  The prophylactic / therapeutic agent according to claim 1, wherein the inflammatory bowel disease is ulcerative colitis. 炎症性腸疾患が、出血性直腸潰瘍である請求項１記載の予防・治療剤。  The prophylactic / therapeutic agent according to claim 1, wherein the inflammatory bowel disease is hemorrhagic rectal ulcer. 炎症性腸疾患が、回腸嚢炎である請求項１記載の予防・治療剤。  The prophylactic / therapeutic agent according to claim 1, wherein the inflammatory bowel disease is ileal cystitis. 式（Ｉ）：
Figure 2002104962
で示される化合物またはその薬理学的に許容しうる塩を有効成分としてなることを特徴とする消化管の狭窄防止剤。Formula (I) :
Figure 2002104962
 Or a pharmacologically acceptable salt thereof as an active ingredient. 消化管の狭窄が、炎症性腸疾患に起因する腸管の狭窄である請求項１２記載の防止剤。13. The inhibitor according to claim 12 , wherein the stenosis of the digestive tract is stenosis of the intestinal tract due to inflammatory bowel disease. 式（Ｉ）：
Figure 2002104962
で示される化合物またはその薬理学的に許容しうる塩を有効成分としてなることを特徴とする人工肛門周囲の炎症の予防・治療剤。Formula (I) :
Figure 2002104962
 Or a pharmacologically acceptable salt thereof as an active ingredient.
JP2000341840A 1999-11-11 2000-11-09 Prevention and treatment of inflammatory bowel disease Expired - Fee Related JP3587247B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2000341840A JP3587247B2 (en) 1999-11-11 2000-11-09 Prevention and treatment of inflammatory bowel disease

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP32105899 1999-11-11
JP11-321058 2000-07-26
JP2000225442 2000-07-26
JP2000-225442 2000-07-26
JP2000341840A JP3587247B2 (en) 1999-11-11 2000-11-09 Prevention and treatment of inflammatory bowel disease

Publications (3)

Publication Number Publication Date
JP2002104962A JP2002104962A (en) 2002-04-10
JP3587247B2 JP3587247B2 (en) 2004-11-10
JP2002104962A5 true JP2002104962A5 (en) 2005-04-14

Family

ID=27339823

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000341840A Expired - Fee Related JP3587247B2 (en) 1999-11-11 2000-11-09 Prevention and treatment of inflammatory bowel disease

Country Status (1)

Country Link
JP (1) JP3587247B2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1380294A1 (en) * 2001-04-17 2004-01-14 Tanabe Seiyaku Co., Ltd. Preventive/remedial agent for inflammatory disease in oral-cavity mucosa and the like
KR102204406B1 (en) * 2019-01-23 2021-01-18 (주)샤페론 Composition for preventing or treating of inflammatory bowel disease comprising taurodeoxycholic acid or pharmaceutically acceptable salts thereof as an active ingredient
CN114790204B (en) * 2021-01-26 2024-05-03 成都贝诺科成生物科技有限公司 Compound for preventing and treating intestinal diseases and pharmaceutical composition thereof

Similar Documents

Publication Publication Date Title
JP5671560B2 (en) Tetracycline metal complexes in solid dosage forms.
JP2021063088A5 (en)
RU2005135016A (en) Quinoline derivatives as phosphodiesterase inhibitors
JP2006526590A5 (en)
JP2006515838A5 (en)
JP2010077141A5 (en)
JP2002504112A (en) Film-coated tablets to enhance upper gastrointestinal tract safety
JP2005525345A5 (en)
JPH07501073A (en) risedronate delayed release composition
JP2011190259A5 (en)
JP2008534592A5 (en)
US6197341B1 (en) Formulations of balsalazide and its derivatives
JPH01268633A (en) L-doper rectum absorbable form
JP2001526234A5 (en)
JP2005513014A5 (en)
JPH02268178A (en) Anti-inflammatory preparation containing 3-formylamino-7-methylsulfonylamino-6-phenoxy-4h-1-benzopyran-4-one or its salt
CA2389032A1 (en) Preventive or therapeutic agents for inflammatory diseases of intestine
JP2003508467A5 (en)
JP2002520315A5 (en)
JP2002104962A5 (en)
JP2002509154A5 (en)
EP2629778B1 (en) Use of mexiprostil in the treatment of inflammatory bowel disease and/or of irritable bowel syndrome
JP2003522782A5 (en)
CA1124648A (en) Anti-inflammatory combination having reduced ulcerogenicity
JP2005516066A5 (en)